CNR Institute of Neuroscience and BIOMETRA Department, Università degli Studi di Milano, Milan, Italy.
Traffic. 2018 Mar;19(3):182-197. doi: 10.1111/tra.12550.
Tail-anchored (TA) proteins insert into their target organelles by incompletely elucidated posttranslational pathways. Some TA proteins spontaneously insert into protein-free liposomes, yet target a specific organelle in vivo. Two spontaneously inserting cytochrome b5 forms, b5-ER and b5-RR, which differ only in the charge of the C-terminal region, target the endoplasmic reticulum (ER) or the mitochondrial outer membrane (MOM), respectively. To bridge the gap between the cell-free and in cellula results, we analyzed targeting in digitonin-permeabilized adherent HeLa cells. In the absence of cytosol, the MOM was the destination of both b5 forms, whereas in cytosol the C-terminal negative charge of b5-ER determined targeting to the ER. Inhibition of the transmembrane recognition complex (TRC) pathway only partially reduced b5 targeting, while strongly affecting the classical TRC substrate synaptobrevin 2 (Syb2). To identify additional pathways, we tested a number of small inhibitors, and found that Eeyarestatin I (ES ) reduced insertion of b5-ER and of another spontaneously inserting TA protein, while not affecting Syb2. The effect was independent from the known targets of ES , Sec61 and p97/VCP. Our results demonstrate that the MOM is the preferred destination of spontaneously inserting TA proteins, regardless of their C-terminal charge, and reveal a novel, substrate-specific ER-targeting pathway.
尾部锚定(TA)蛋白通过尚未完全阐明的翻译后途径插入其靶细胞器。一些 TA 蛋白自发插入无蛋白脂质体,但在体内靶向特定细胞器。两种自发插入的细胞色素 b5 形式,b5-ER 和 b5-RR,仅在 C 末端区域的电荷上有所不同,分别靶向内质网(ER)或线粒体外膜(MOM)。为了弥合无细胞和细胞内结果之间的差距,我们分析了在胆酸钠通透的贴壁 HeLa 细胞中的靶向。在没有细胞质的情况下,两种 b5 形式的靶标都是 MOM,而在细胞质中,b5-ER 的 C 末端负电荷决定了其靶向 ER。跨膜识别复合物(TRC)途径的抑制剂仅部分减少了 b5 的靶向,而强烈影响经典的 TRC 底物突触融合蛋白 2(Syb2)。为了鉴定其他途径,我们测试了许多小分子抑制剂,发现 Eeyarestatin I(ES)减少了 b5-ER 和另一种自发插入的 TA 蛋白的插入,而不影响 Syb2。该效果独立于 ES 的已知靶标 Sec61 和 p97/VCP。我们的结果表明,MOM 是自发插入 TA 蛋白的首选靶标,与它们的 C 末端电荷无关,并揭示了一种新的、底物特异性的 ER 靶向途径。